<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185066</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_ATM_103</org_study_id>
    <nct_id>NCT02185066</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety and pharmacokinetic properties of the two
      treatments, the administration of CJ-30056 and the co-administration of atorvastatin and
      metformin XR, in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Atorvastatin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Metformin</measure>
    <time_frame>Upto 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration-time Curve (AUC0-t) of Atorvastatin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration-time Curve (AUC0-t) of Metformin</measure>
    <time_frame>Upto 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of 2-OH-atorvastatin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma concentration-time Curve (AUC0-t) of 2-OH-atorvastatin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Atorvastatin and Metformin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Atorvastatin and Metformin</measure>
    <time_frame>Upto 36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose crossover
Reference: Atorvastatin 20mg and Metformin XR 500mg
Test: CJ-30056 20/500mg
Once daily Oral administration with 7days of washout period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose crossover
Test: CJ-30056 20/500mg
Reference: Atorvastatin 20mg and Metformin XR 500mg
Once daily Oral administration with 7days of washout period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg and Metformin XR 500mg (Reference)</intervention_name>
    <description>Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30056 20/500mg (Test)</intervention_name>
    <description>Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to adhere to protocol requirements and sign a informed consent form

          2. Male volunteers in the age between 19 and 55 years old and have the weight range is
             not exceed Â±20% of ideal weight

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

        Exclusion Criteria:

          1. Use of barbital inducer or inhibitor medication within the 4 weeks before dosing

          2. Symptom of an acute illness within 4 weeks prior to drug administration

          3. History of clinically significant hepatic, renal, gastrointestinal diseases which
             might significantly interfere with ADME

          4. History of surgery except or gastrointestinal diseases which might significantly
             change absorption of medicines

          5. History of clinically significant allergies including drug allergies

          6. History of clinically significant allergies about atorvastatin or metformin

          7. Subjects who have ever or have plan to do intravenous injection of contrast medium
             (intravenous urography, intravenous cholangiography, computed tomography using
             contrast medium) within 28 days prior to drug administration

          8. History of myopathy

          9. Clinical laboratory test values are outside the accepted normal range

               -  AST or ALT &gt;1.25 times to normal range

               -  Total bilirubin &gt;1.5 times to normal range

               -  e-GFR &lt;90 mL/min

         10. History of drug, caffein(caffein &gt; 5 cups/day), smoking (cigarette &gt; 10/day) or
             alcohol abuse(alcohol &gt; 30 g/day)or Subjects who have ever drink within 7 days prior
             to drug administration

         11. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         12. Donated blood within 60 days prior to dosing

         13. Participated in a previous clinical trial within 60 days prior to dosing

         14. Use of any other medication, including herbal products, within 10 days before dosing

         15. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-lyul Ghim, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

